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Abstract
Aims/hypothesis Metformin is the most-prescribed oral med-
ication to lower blood glucose worldwide. Yet previous sys-
tematic reviews have raised doubts about its effectiveness in
reducing risk of cardiovascular disease, the most costly com-
plication of type 2 diabetes. We aimed to systematically iden-
tify and pool randomised trials reporting cardiovascular out-
comes in which the effect of metformin was ‘isolated’ through
comparison to diet, lifestyle or placebo.
Methods We performed an electronic literature search of
MEDLINE, EMBASE and the Cochrane Library.We also man-
ually screened the reference lists of previous meta-analyses of
trials of metformin identified through a MEDLINE search. We
included randomised controlled trials of adults with type 2 dia-
betes comparing any dose and preparation of oral metformin
with no intervention, placebo or a lifestyle intervention and
reporting mortality or a cardiovascular outcome.
Results We included ten articles reporting 13 trials (including a
total of 2079 individuals with type 2 diabetes allocated to met-
formin and a similar number to comparison groups) of which
only four compared metformin with placebo and collected data
on cardiovascular outcomes. Participants were mainly white,
aged ≤65 years, overweight/obese and with poor glycaemic
control. Summary estimates were based on a small number of
events: 416 myocardial infarctions/ischaemic heart disease
events in seven studies and 111 strokes in four studies. The
UK Prospective Diabetes Study (UKPDS) contributed the ma-
jority of data to the summary estimates, with weights ranging
from 52.3% for myocardial infarction to 70.5% for stroke. All
outcomes, with the exception of stroke, favoured metformin,
with limited heterogeneity between studies, but none achieved
statistical significance. Effect sizes (Mantel–Haenszel RR)
were: all-cause mortality 0.96 (95% CI 0.84, 1.09); cardiovas-
cular death 0.97 (95% CI 0.80, 1.16); myocardial infarction
0.89 (95% CI 0.75, 1.06); stroke 1.04 (95% CI 0.73, 1.48);
and peripheral vascular disease 0.81 (95% CI 0.50, 1.31).
Conclusions/interpretation There remains uncertainty about
whether metformin reduces risk of cardiovascular disease
among patients with type 2 diabetes, for whom it is the recom-
mended first-line drug. Although this is mainly due to absence
of evidence, it is unlikely that a definitive placebo-controlled
cardiovascular endpoint trial among people with diabetes will
be forthcoming. Alternative approaches to reduce the uncer-
tainty include the use of electronic health records in long-term
pragmatic evaluations, inclusion ofmetformin in factorial trials,
publication of cardiovascular outcome data from adverse event
reporting in trials of metformin and a cardiovascular endpoint
trial of metformin among people without diabetes.
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Introduction
The aims of prescribing medication to lower glucose among
people with type 2 diabetes are to reduce the symptoms of
hyperglycaemia and the risk of microvascular and
macrovascular complications. Since ancient times, a range of
therapies have been effective at alleviating the polydipsia and
polyuria associated with raised blood glucose levels. Twenty
years ago, trial evidence finally emerged showing that lower-
ing blood glucose reduced risks of microvascular complica-
tions among people with type 2 diabetes [1]. However, subse-
quent randomised trials evaluating the effects of intensive
treatment for the regulation of blood glucose have highlighted
concerns about adverse effects, in particular hypoglycaemia
and mortality, and demonstrated inconsistent findings for risk
of micro- and macrovascular complications [2, 3]. The evi-
dence of benefit appears stronger for micro- than
macrovascular disease [4], albeit the latter represents the
greatest burden to healthcare and society. The situation is fur-
ther complicated by the heterogeneity in findings of observa-
tional studies [5] and randomised trials of different drugs (and
combinations of drugs [6]) used to lower blood glucose, even
those with apparently similar pharmacological targets [7–10].
The biguanide metformin has had an interesting history.
After an inauspicious debut, a somewhat circuitous route (in-
cluding use as a treatment for infectious disease), the withdrawal
of phenformin and buformin (the only other biguanides used to
lower blood glucose) following trial evidence of harm [11] and
publication of the UK Prospective Diabetes Study (UKPDS)
results, showing evidence of cardiovascular benefits [12], met-
formin was introduced in the USA in 1995 and has emerged as
the first-choice and most-prescribed oral medication to lower
blood glucose worldwide [13]. However, recent systematic re-
views have raised doubts about the effectiveness of metformin
in reducing risk of complications [14, 15]. In these reviews, data
were pooled from predominantly small trials with short follow-
up in which metformin was evaluated against a range of com-
parators that have heterogenous associations with risk of cardio-
vascular disease. This has constrained interpretation of the ben-
efits and harms of metformin. Since 2008, the US Food and
Drug Administration (FDA) have required demonstration of
cardiovascular safety prior to the licensing of new glucose-
lowering drugs. Several placebo-controlled trials of glucose-
lowering drugs, incorporating cardiovascular endpoints, have
reported findings or are underway [16]. Consequently, the avail-
ability of data to inform treatment guidelines and prescribing
decisions for patients is increasing. In this changing context, it
therefore seems timely to review the evidence for cardiovascular
disease prevention with metformin.
As part of a series of papers to acknowledge the sixtieth
anniversary of the first use of metformin for the treatment of
type 2 diabetes in this issue of Diabetologia, we appraise the
evidence concerning the effectiveness of metformin in
preventing cardiovascular disease in patients with type 2 dia-
betes by undertaking a meta-analysis. We aimed to systemat-
ically identify and pool randomised trials reporting cardiovas-
cular outcomes in which the effect of metforminwas ‘isolated’
through comparison to diet, lifestyle or placebo, rather than
alternative glucose-lowering medication.
Methods
We undertook a systematic review and meta-analysis follow-
ing the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [17].
Search strategyWe performed an electronic literature search
ofMEDLINE (1 January 1967 to 6 February 2017; www.ncbi.
nlm.nih.gov/m/pubmed), EMBASE (1 January 1947 to 28
February 2017; https://login.webofknowledge.com) and the
Cochrane Library (1 January 1967 to 28 February 2017;
www.cochranelibrary.com;), with no language limits, using
search terms (shown in the Text box) adapted from an earlier
Cochrane review [18]. We also performed an electronic
literature search of MEDLINE, with no language or date
limits, for papers with ‘meta-analysis’ and ‘metformin’ in
the title. We manually screened the reference lists of
identified meta-analyses. Finally, we manually screened the
reference list of a recent systematic review of cardiovascular
endpoint trials of glucose-lowering medication [16].
Literature search terms
Diabetes mellitus, non-insulin-dependent 
[MeSH, all subheadings included]
NIDDM
“Non-insulin-dependent” or “Noninsulin-
dependent” or “Non insulin dependent”
“Type II diabet*” or “Type 2 diabet*”
no. 1 or no. 2 or no. 3 or no. 4
Biguanides [MeSH, all subheadings included]
Biguanides*
Metformin [MeSH, all subheadings included]
Glucophag*
Metformin*
no. 6 or no. 7 or no. 8 or no. 9 or no. 10
no. 5 and no. 11
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Diabetologia (2017) 60:1620–1629 1621
Study selection We included studies if they fulfilled all of the
following criteria: randomised controlled trial among adults
with type 2 diabetes comparing any dose and preparation of
oral metformin with no intervention, or with placebo or a life-
style intervention, and reporting mortality or a cardiovascular
outcome (cardiovascular death, myocardial infarction, stroke or
peripheral vascular disease) as a primary or secondary outcome
or adverse event. There was no restriction based on duration of
follow-up. We included studies in which metformin was com-
bined with another drug as long as the comparator group was
given the other drug at the same dose as used in the metformin
combined therapy group, thereby controlling for the effects
(either positive or negative) of the other drug and ‘isolating’
the impact of metformin.We excluded quasi-experimental stud-
ies, crossover and observational studies, and studies including
children, pregnant women and people with impaired glucose
tolerance. Two authors (G. Irving and J. Leaver) independently
screened titles and abstracts identified by the MEDLINE search
to exclude papers that were clearly not relevant. Any disagree-
ment was solved by discussion with S. Griffin. The full text was
examined by one author (G. Irving) if a definite decision to
reject could not be made based on title and abstract alone. The
full text of all included studies was reviewed by a second author
(S. Griffin). After excluding duplicates, one author (G. Irving)
repeated the process for the results of the EMBASE search.
Data extraction and synthesis Data concerning study size,
interventions, inclusion criteria, duration of follow-up, partic-
ipant characteristics (for the metformin group) and outcomes
were extracted independently by at least two out of the three
authors and any disagreement was resolved by discussion. We
assessed risk of bias in included trials according to the
methods recommended by the Cochrane Collaboration. We
combined outcome data from different studies using fixed
effects meta-analysis and presented data as Mantel–Haenszel
(M–H) RRs and 95% CI. When one article reported multiple
comparisons, we treated each as a separate study (these are
labelled as ‘a’ and ‘b’ in tables and figures). For factorial
designs, we included overall comparisons between metformin
and placebo groups. When data from one study were reported
in more than one article we extracted the most recently pub-
lished data. For outcomes with data from three or more stud-
ies, we assessed heterogeneity between studies using the I2
statistic. We assessed the risk of publication bias by producing
a funnel plot for all-cause mortality. We used RevMan version
5.3 for analyses (http://community.cochrane.org/tools/review-
production-tools/revman-5/revman-5-download).
Results
After removal of duplicates, the initial electronic search iden-
tified 20,268 articles (Fig. 1). Following screening of titles and
abstracts, we reviewed the full text of 98 articles and included
ten articles reporting 13 trials of metformin. The commonest
reasons for exclusion at the full text stage were the presence of
an active comparator or the absence of text describing the
collection of data for cardiovascular events as a study outcome
or adverse event.
The characteristics of included studies are shown in
Table 1. Studies reported between 1995 and 2011. Six were
undertaken in Northern Europe [12, 19–23], six in North
America [24–26] and one in Israel [27]. Three studies were
open-label [12, 21, 27], one of which was a trial of cessation of
metformin [27]. Of the ten placebo-controlled trials, six in-
cluded other glucose-lowering drugs. We identified four trials
including 417 patients allocated to metformin that simply
compared metformin with placebo and collected data on car-
diovascular outcomes [19, 24–26]. In total 2079 patients with
type 2 diabetes were allocated to metformin, and a similar
number to comparison groups, in the included studies.
Duration of follow-up ranged from 6 to 212 months; three
studies followed patients up for more than 4 years [12, 21,
22]. No studies were assessed as having low risk of bias
(Fig. 2). The average age of recruited participants ranged from
53 to 65 years and exceeded 60 years in two studies [22, 27].
Trial participants tended to be mainly white, overweight/obese
(average baseline BMI ranged from 28.7 to 34.2 kg/m2), with
longstanding (average duration ranged from 0 years in two
Database searching:
MEDLINE (n = 8413)
EMBASE (n = 8654)
Cochrane Library (n = 3373)
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Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram [40]
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studies [19, 21] to 15 years [27]) and poorly controlled diabetes
(average baseline HbA1c was less than 8% [63.9 mmol/mol]
in only four studies [12, 19, 21, 22] and ranged from 6.9%
[51.9 mmol/mol] to 9.1% [76.0 mmol/mol]).
The effect of metformin on risk of all-cause mortality
(Fig. 3), cardiovascular death (Fig. 4), myocardial infarction
(Fig. 5), stroke (Fig. 6) and peripheral vascular disease (Fig. 7)
is shown. All outcomes, with the exception of risk of stroke,
favoured metformin, with limited heterogeneity between stud-
ies, but none achieved statistical significance. Effect sizes
(M–H RR) ranged from 0.81 (95% CI 0.50, 1.31) for periph-
eral vascular disease to 1.04 (95% CI 0.73, 1.48) for stroke.
Summary estimates were based on a small number of events:
347 cardiovascular deaths in five studies, 416 myocardial
infarcts/ischaemic heart disease events in seven studies and
111 strokes in four studies. One study, the UKPDS [21],
contributed the majority of data to the summary estimates,
with weights ranging from 52.3% for myocardial infarction
to 70.5% for stroke. We undertook a sensitivity analysis re-
placing data from the longer term follow-up of UKPDS [21]
with the original published data [12]. This led to small chang-
es in the pooled estimates that more strongly favoured metfor-
min for risk of stroke but more strongly favoured comparison
groups for risk of myocardial infarction and peripheral vascu-
lar disease. All of the pooled estimates in the sensitivity analy-
sis remained non-significant (metformin vs control). The fun-
nel plot (Fig. 8) did not suggest that we had omitted trials
demonstrating metformin-associated increased mortality.
Discussion
In spite of its long history, we identified only 13 studies, in-
cluding just over 2000 patients with type 2 diabetes allocated
to metformin, that addressed our study question, and only four
randomised-controlled cardiovascular endpoint trials simply
comparing metformin with placebo among patients with type
2 diabetes. Metformin monotherapy appears safe and, while
there is a suggestion of benefit, there remains uncertainty
about whether it reduces risk of cardiovascular disease.
According to our review it is possible that metformin reduces
risk of all-cause mortality by up to 16% but it could increase
risk of stroke by up to 48%. Metformin is the recommended
first-line treatment worldwide for patients with type 2 diabe-
tes. However, in contrast to some newer treatments, cardio-
vascular endpoint trial data for metformin are largely derived
from small studies among relatively young, overweight/obese,
North American and Northern European patients with poorly
controlled diabetes. Metformin demonstrates cardiovascular
safety as per the 2008 FDA guidance, but its use for preven-
tion of cardiovascular disease among older individuals, those
with HbA1c less than 8% (63.9 mmol/mol), non-white ethnic
groups and people living outside North America and Northern
Europe is not well supported by trial evidence. Furthermore,
while not specifically covered in this review, there remains
concern about the observed increased risk of mortality associ-
ated with the addition of metformin to sulfonylurea treatment
[14, 15].
The reports of all included trials either suggested the pos-
sibility of bias or provided insufficient information to allow
risk of bias to be assessed. The one trial that appeared to
exhibit low risk of bias for all but one criterion seemed to be
compromised by clinically important baseline differences be-
tween study groups [22]. The majority of data for this review
came from the UKPDS [21], a seminal trial concerning the
effectiveness and safety of treatments for type 2 diabetes, al-
beit exhibiting a number of previously discussed limitations
that might influence its interpretation [28]. These include the
small size (only 342 patients were allocated to metformin),
Chiasson et al (2001a) [24]
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Holman et al (2008) [21]
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lack of placebo and double-blinding, ‘subgroup’ nature of the
analysis with updated statistical significance thresholds, po-
tential for between-group differences in management of other
cardiovascular risk factors, unacceptably poor level of
glycaemic control in the comparison group by current stan-
dards, and attrition over the near 18-year follow-up. Including
data from the long-term follow-up of the UKPDS [21] intro-
duces a number of assumptions that may lead to underestima-
tion of effects, in particular the extent of any ‘legacy effect’ of
treatment with metformin in the early part of the trial.
However, a sensitivity analysis replacing the longer term
follow-up with the original UKPDS trial data [12] increased
the width of the 95% CIs but did not significantly change our
findings.
Strengths and weaknesses We used a sensitive search strat-
egy and systematically searched literature databases and ref-
erence lists of previous systematic reviews. However, we only
searched three databases and may have excluded trials that are
not indexed on MEDLINE or EMBASE or are unpublished.
We only included trials that ‘isolated’ the effects of metformin
in order to distinguish between benefits of metformin and
harms associated with comparator drugs. With the exception
of screening of some of the full text articles, the reviewing
process was undertaken by two authors independently. We
undertook quality assessment but included all trials meeting
our pre-specified criteria. Definitions of the different cardio-
vascular outcomes varied between studies, particularly for pe-
ripheral vascular disease, which included angiographic find-
ings in Kooy et al [22] but was restricted to amputation or
death because of peripheral vascular disease in Holman et al
[21]. We erred on the side of sensitivity to maximise the num-
ber of events, for example, including ‘ischaemic heart disease’
endpoints in Gram et al [23] as myocardial infarctions.
Reporting of adverse events was inconsistent; consequently,
for trials in which cardiovascular events were not specified as
Favours (metformin) Favours (control)
Heterogeneity:   2 = 8.76, df = 5 (p = 0.12); I 2 = 43%
Metformin
Study or subgroup
Chiasson et al (2001a) [24] 0 83
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2 184
0
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0
0
0
2
016
0 135
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268
2042 2114 100.0 % 0.96 (0.84, 1.09)
273 320
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0
0
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64
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1.02 (0.14, 7.14)
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1.48 (0.54, 4.09)
0.98 (0.74, 1.31)
1.52 (1.00, 2.32)
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0.84 (0.72, 0.98)342
83
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study outcomes, it was not always clear from the text of arti-
cles whether or not these data were collected as part of the
monitoring for adverse events. It was also not possible to
obtain clarification from authors and so we may have exclud-
ed some studies in which relevant data had been collected.
However, the number of missed events is likely to be small
in studies in which cardiovascular disease was not the main
focus and, hence, the impact on summary estimates and con-
clusions negligible.
Comparison with existing literature Unsurprisingly, given
the influence of the UKPDS data on this analysis and the
overlap of the review question and included studies, our re-
sults are broadly similar to those of previous reviews pub-
lished within the last 10 years [14, 15, 29]. In Selvin et al’s
meta-analysis of trials of metformin vs any comparator, effect
sizes for cardiovascular and all-causemortality (M–HOR 0.74
[95% CI 0.62, 0.89] and M–H OR 0.81 [95% CI 0.60, 1.08],
respectively) more strongly favoured metformin [29], mainly
because of the inclusion of the open-label, active-comparator
trial, the Comparative Outcomes Study of Metformin
Intervention versus Conventional (COSMIC) Approach
Study [30]. Lamanna et al’s meta-analysis, which included
trials of diabetes prevention and trials with active comparators
(in particular rosiglitazone), reported no overall effect of met-
formin on cardiovascular events (M–HOR0.94 [95%CI 0.82,
1.07]) [15]. When analysis was restricted to comparisons of
metformin with placebo or no drug treatment, metformin ap-
peared to be beneficial (M–H OR 0.79 [95% CI 0.64, 0.98]).
Our results most closely mirror those of Boussageon et al [14],
who reported no effect of metformin on all-cause mortality
(M–H RR 0.99 [95% CI 0.75, 1.31]) or cardiovascular mor-
tality (M–H RR 1.05 [95%CI 0.67, 1.64]), but did not include
the extended follow-up data from the UKPDS.
Implications Metformin lowers glucose and, hence, reduces
symptoms of hyperglycaemia. It has a good safety profile,
even among patients with impaired renal function [31], is
relatively well tolerated and may even reduce cancer inci-
dence and mortality [32], although this was not confirmed in
a meta-analysis of trials [33]. The number, size, quality,
reporting and findings of randomised trials of metformin have
resulted in continuing uncertainty regarding whether it re-
duces risk of diabetes-related complications, particularly car-
diovascular disease. Furthermore, there is a lack of cardiovas-
cular endpoint data directly relevant to a significant proportion
of the patients with type 2 diabetes worldwide for whom met-
formin is the recommended first-line medication. This con-
trasts with the evidence now available for newer and more
expensive glucose-lowering drugs, such as empagliflozin
[34] and liraglutide [10], and of course for medications
targeting different risk factors, for example statins.
Nevertheless, metformin is included on the WHO model list
of essential medicines, a list of ‘the most efficacious, safe and
cost-effective medicines for priority conditions’ and the ‘min-
imum medicine needs for a basic health-care system’. It is
unlikely that patients, practitioners and ethics committees are
all sufficiently close to equipoise to enable a large, double-
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blind, placebo-controlled, cardiovascular endpoint trial of
metformin among patients with diabetes. It is also doubtful
that a suitable industry, charity or government funder could be
identified. While such a trial might reduce uncertainty about
whether metformin is more effective than placebo, it would
not inform common therapeutic dilemmas, such as which of
the many available glucose-lowering drugs or combination of
drugs to use, in which order to use them and for which patient.
Possible, at least partial, solutions include the use of electronic
health records to facilitate large, long-term, pragmatic, effi-
cient trials comparing the effect of different treatments (new
and old) on cardiovascular outcomes, plus the increased use of
factorial trials in which an industry-sponsored newmedication
can be evaluated alongside older drugs such as metformin.
There has been considerable hope and hype concerning the
potential for precision medicine to inform treatment decisions
[35], but progress is hampered by our lack of understanding
about the mechanisms of action of metformin and a focus on
intermediate endpoints. Publication of cardiovascular out-
come data from adverse event reporting in trials of metformin
would increase the data available for meta-analysis, thereby
reducing the uncertainty of effect size estimates, but the small
number of additional events are unlikely to lead to definitive
conclusions.
Metformin reduced the incidence of diabetes by 31%
among people with glucose levels just below the diagnostic
threshold in the US Diabetes Prevention Programme [36], and
by 26% in the Indian equivalent [37]. Although, these esti-
mates were inflated because of participants undergoing out-
come assessment while still taking metformin [38].
Proponents of a medical solution to what is essentially a soci-
etal problem are advocating the widespread use of metformin
to ‘treat’ those at risk of diabetes. Indeed, metformin is now
licensed in some countries for this indication. This effectively
amounts to starting glucose-lowering treatment early in order
to prevent the onset of diabetes and the need for glucose-
lowering treatment, the aim of which is to reduce symptoms
and risk of complications. Given that people at risk of diabetes
do not have symptoms attributable to hyperglycaemia, the
rationale for recommendingmetformin would be considerably
strengthened if trial evidence was available demonstrating that
the use of metformin in people at risk of diabetes reduced risk
of complications, such as cardiovascular disease. Perhaps,
therefore, there is greater interest, opportunity and need for a
cardiovascular endpoint trial evaluation of metformin among
people without diabetes than among those already living with
the condition.While acknowledging that metformin has pleio-
tropic effects, if it was shown to be effective in such a trial, the
near-linear relationship between HbA1c and risk of cardiovas-
cular disease and death [39], and the somewhat arbitrary di-
agnostic threshold for diabetes, might also reinforce the repu-
tation of metformin for treating diabetes. Metformin is cheap,
widely available, safe, backed by pharmaco-epidemiological
and anecdotal evidence following up to 60 years of regular use
in practice, and appears more likely to reduce risk of cardio-
vascular disease than increase it. Albeit, the latter assessment
is based on a few small trials, with notable limitations, among
an unrepresentative subset of patients. Newer agents that
could potentially be used early in the course of the disease
are now available, and are backed by data from recent rigorous
cardiovascular endpoint trials. However, they remain very ex-
pensive and lack data on long-term use. Perhaps in spite of,
rather than because of, the evidence, metformin is likely to
remain the first-line treatment for the hyperglycaemia associ-
ated with type 2 diabetes for the foreseeable future.
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